<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05799040</url>
  </required_header>
  <id_info>
    <org_study_id>2022-NHLHCRF-LX-01-0202-3</org_study_id>
    <nct_id>NCT05799040</nct_id>
  </id_info>
  <brief_title>Evaluation of the Effectiveness of the Self-developed Pulmonary Lobar Ventilation Detector</brief_title>
  <official_title>Evaluation of the Effectiveness of the Self-developed Pulmonary Lobar Ventilation Detector</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>China-Japan Friendship Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>China-Japan Friendship Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of observational study is to Evaluation of the effectiveness of the self-developed&#xD;
      pulmonary lobar ventilation detector in Chronic Obstructive Pulmonary Disease. The main&#xD;
      question it aims to answer are:Evaluation of the effectiveness of the self-developed&#xD;
      pulmonary lobar ventilation detector.&#xD;
&#xD;
      Participants will use the self-developed pulmonary lobar ventilation detector and the&#xD;
      imported Chartis detection system to evaluate the target pulmonary lobar collateral&#xD;
      ventilation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 30, 2023</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Therapeutic effect of lung volume reduction surgery</measure>
    <time_frame>1 month after bronchoscopic valve lung volume reduction</time_frame>
    <description>Lung CT</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Therapeutic effect of lung volume reduction surgery</measure>
    <time_frame>3 months after bronchoscopic valve lung volume reduction</time_frame>
    <description>Lung CT</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Therapeutic effect of lung volume reduction surgery</measure>
    <time_frame>6 months after bronchoscopic valve lung volume reduction</time_frame>
    <description>Lung CT</description>
  </primary_outcome>
  <primary_outcome>
    <measure>the integrity of interlobar fissure</measure>
    <time_frame>Before bronchoscopic valve lung volume reduction</time_frame>
    <description>Use the self-developed pulmonary lobar ventilation detector and the imported Chartis detection system to evaluate the target pulmonary lobar collateral ventilation</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>Self-developed pulmonary lobar ventilation detector</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>imported Chartis detection system</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Self-developed pulmonary lobar ventilation detector</intervention_name>
    <description>The participants would evaluated by the self-developed pulmonary lobar ventilation detector.</description>
    <arm_group_label>Self-developed pulmonary lobar ventilation detector</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Chartis detection system</intervention_name>
    <description>The participants would evaluated by the Chartis detection system.</description>
    <arm_group_label>imported Chartis detection system</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Chronic obstructive pulmonary disease&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with chronic obstructive pulmonary disease who meet the GOLD diagnostic&#xD;
             criteria&#xD;
&#xD;
          -  FEV1 ≤ 45% pred and FEV1/FVC&lt;70%&#xD;
&#xD;
          -  TLC&gt;100% pred and RV&gt;175% pred&#xD;
&#xD;
          -  CAT≥18&#xD;
&#xD;
          -  &gt;50% of emphysema destruction&#xD;
&#xD;
          -  Smoking prohibition&gt;6 months&#xD;
&#xD;
          -  Sign the informed consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  PaCO2&gt;8.0 kPa, or PaO2&lt;6.0 kPa&#xD;
&#xD;
          -  6-minute walking test&lt;160m&#xD;
&#xD;
          -  Obvious chronic bronchitis, bronchiectasis or other infectious lung diseases&#xD;
&#xD;
          -  Three hospitalizations due to pulmonary infection in the past 12 months before the&#xD;
             baseline assessment&#xD;
&#xD;
          -  Previous lobectomy, LVRS or lung transplantation&#xD;
&#xD;
          -  LVEF&lt;45% and or RVSP&gt;50mmHg&#xD;
&#xD;
          -  Anticoagulant therapy that cannot be stopped before surgery&#xD;
&#xD;
          -  The patient has obvious immune deficiency&#xD;
&#xD;
          -  Participated in other lung drug studies within 30 days before this study&#xD;
&#xD;
          -  Pulmonary nodules requiring intervention&#xD;
&#xD;
          -  Any disease or condition that interferes with the completion of the initial or&#xD;
             subsequent assessment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mingming Deng, MD</last_name>
    <phone>86 18801336854</phone>
    <email>isdeng1017@163.com</email>
  </overall_contact>
  <verification_date>March 2023</verification_date>
  <study_first_submitted>March 9, 2023</study_first_submitted>
  <study_first_submitted_qc>March 22, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">April 5, 2023</study_first_posted>
  <last_update_submitted>March 22, 2023</last_update_submitted>
  <last_update_submitted_qc>March 22, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>China-Japan Friendship Hospital</investigator_affiliation>
    <investigator_full_name>Gang Hou</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

